-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KqRmvCK8WbmEOvkPvp4AKuT2I7prRn1NB1jvNJezKK+ErdRtziEy272lFEwYsolg tvtGPHYW9X5HNu70/E3vcw== /in/edgar/work/0000950117-00-002256/0000950117-00-002256.txt : 20001005 0000950117-00-002256.hdr.sgml : 20001005 ACCESSION NUMBER: 0000950117-00-002256 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20000922 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 20001004 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ORTEC INTERNATIONAL INC CENTRAL INDEX KEY: 0000889992 STANDARD INDUSTRIAL CLASSIFICATION: [8071 ] IRS NUMBER: 113068704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-27368 FILM NUMBER: 734876 BUSINESS ADDRESS: STREET 1: 3960 BROADWAY STREET 2: BLDG 28 CITY: NEW YORK STATE: NY ZIP: 10032 BUSINESS PHONE: 7183264698 8-K 1 0001.txt ORTEC INTERNATIONAL, INC. 8-K ============================================================================== SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ---------------- FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2000 (September 22, 2000) ORTEC INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-27368 11-3068704 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification No.) 3960 Broadway New York, New York 10032 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code:(212) 740-6999 ORTEC INTERNATIONAL, INC. INDEX TO FORM 8-K FILED WITH THE SECURITIES AND EXCHANGE COMMISSION OCTOBER 4, 2000 ITEMS IN FORM 8-K -----------------
Page ---- Facing page Item 5. Other Events 3 Item 7. Financial Statements and Exhibits 4 Signatures Exhibit Index
2 ITEM 5. OTHER EVENTS. On September 22, 2000, the Company extended the expiration date of its publicly traded Class B warrants from September 28, 2000 to December 31, 2000. Such action was taken by the Company's Board of Directors. There are 1,188,600 Class B Warrants outstanding. Each Class B warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $15 per share. The closing price for the Company's Common Stock on the Nasdaq SmallCap Market on October 3, 2000 was $9.94. The original expiration date of the Class B Warrants was January 18, 1999, but such expiration date was extended by the Company's Board of Directors on six occasions before the action taken on September 22, 2000. Statements in this Current Report on Form 8-K which express the "belief", "anticipation" or "expectation", as well as other statements which are not historical fact, and statements as to future exercise of warrants insofar as they may apply prospectively, are forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties. Actual results may differ significantly from the results discussed in this Current Report on Form 8-K or in other forward-looking statements presented by management. Factors that might cause such a difference include, but are not limited to, development by the Company's competitors of new technologies or products that are more effective than the Company's, risks of failure of clinical trials, dependence on and retention of key personnel, protection of proprietary technology, compliance with U.S. Food and Drug Administration regulations, continued availability of raw material for the Company's products, availability of product liability insurance in the event of commercialization of the Company's products, ability to effect transition from pilot-scale manufacturing to large-scale commercial production of products, uncertainty as to the availability of additional capital on acceptable terms, if at all, and the demand for the Company's products, if and when commercially available. 3 ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS. (c) EXHIBITS.
EXHIBIT NUMBER DESCRIPTION - ------- ----------- 4.1 Form of Warrant Agreement for the Class B Warrants * 4.2 Form of Certificate for the Class B Warrants filed as Exhibit B to Exhibit 4.1*
- ------------------------ * Filed as an exhibit to the Company's Amendment No. 1 to its Registration Statement on Form SB-2 as filed with the Commission on November 15, 1995 (Registration No. 33-96090) and incorporated herein by reference. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 4, 2000 ORTEC INTERNATIONAL, INC. By: /s/ Steven Katz ---------------------- Dr. Steven Katz President 4 EXHIBIT INDEX
EXHIBIT NUMBER DESCRIPTION - -------- ----------- 4.1 Form of Warrant Agreement for the Class B Warrants * 4.2 Form of Certificate for the Class B Warrants filed as Exhibit B to Exhibit 4.1 *
- ------------------------ * Filed as an exhibit to the Company's Amendment No. 1 to its Registration Statement on Form SB-2 as filed with the Commission on November 15, 1995 (Registration No. 33-96090) and incorporated herein by reference. 5 -----END PRIVACY-ENHANCED MESSAGE-----